Monopar Therapeutics, Inc. (MNPR)

NASDAQ: MNPR · IEX Real-Time Price · USD
1.83
-0.03 (-1.35%)
At close: Aug 10, 2022 3:36 PM
1.81
-0.01 (-0.82%)
After-hours: Aug 10, 2022 4:00 PM EDT

Company Description

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.

Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers.

Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer.

The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Monopar Therapeutics, Inc.
Monopar Therapeutics Logo
Country United States
Founded 2014
IPO Date Dec 19, 2019
Industry Biotechnology
Sector Health Care
Employees 9

Contact Details

Address:
1000 Skokie Blvd Ste 350
Wilmette, Illinois 60091-1146
United States
Phone 847 388 0349
Website monopartx.com

Stock Details

Ticker Symbol MNPR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $8.00
CIK Code 1645469
CUSIP Number 61023L108
ISIN Number US61023L1089
SIC Code 2834

Key Executives

Name Position
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc Co-Founder, Chief Executive Officer, President and Director
Kim R. Tsuchimoto CPA Chief Financial Officer, Secretary and Treasurer
Andrew J. Cittadine M.B.A. Chief Operating Officer
Dr. Patrice P. Rioux M.D., Ph.D. Acting Chief Medical Officer

Latest SEC Filings

Date Type Title
Jul 1, 2022 4 Statement of changes in beneficial ownership of securities
Jul 1, 2022 4 Statement of changes in beneficial ownership of securities
Jul 1, 2022 4 Statement of changes in beneficial ownership of securities
Jul 1, 2022 4 Statement of changes in beneficial ownership of securities
Jul 1, 2022 4 Statement of changes in beneficial ownership of securities
Jul 1, 2022 4 Statement of changes in beneficial ownership of securities
Jul 1, 2022 4 Statement of changes in beneficial ownership of securities
Jun 30, 2022 8-K Current report
May 12, 2022 8-K Current report
May 12, 2022 10-Q Quarterly report [Sections 13 or 15(d)]